Mohan Kaadige

Mohan Kaadige Ph.D.

Research Assistant Professor
Applied Cancer Research and Drug Discovery

Mohan Kaadige Ph.D.

Dr. Kaadige is a research scientist with a deep passion for understanding the mechanisms and signaling pathways involved in the development and progression of cancer. At TGen, Dr. Kaadige works closely with Dr. Sharma and Dr. Vankayalapati to develop targeted cancer therapy programs. The team uses a combination of computational drug design, synthetic chemistry and biology to discover small molecule inhibitors for cancer therapy. Dr. Kaadige applies his skills to investigate proof of mechanism for novel inhibitors.

The team is presently investigating SWI/SNF chromatin remodeling complex, as mutations in several genes encoding subunits of this complex have been identified in many cancers. Importantly, mutations in different subunit’s is associated with different types of cancer. For example, SMARCB1 is frequently mutated in rhabdoid tumors; ARID1A in ovarian cancer and SMARCA4 in lung cancer. SWI/SNF complex orchestrates gene expression by recognizing modifications on histone tails and by interactions with numerous transcription factors, coactivators and corepressors. The function of the SWI/SNF complex depends on its subunit’s unique domains such as bromodomain, ATPase domain, ARID domain and E3-ligase activity domain. Targeting any of these domains is a therapeutic opportunity and the team is focused on identifying small molecule inhibitor for one of these domains. Apart from epigenetics, the team is also investigating targets in innate immunity and neuro-oncology.

Dr. Kaadige joined TGen as a Research Assistant Professor in September 2017. He received his PhD from the Wayne State University in 2003 where he studied phospholipid gene expression mechanisms under the guidance of Dr. John Lopes. He joined Huntsman Cancer Institute at the University of Utah for his post-doctoral training and worked as a Research Assistant Professor under the mentorship of Dr. Don Ayer. His research was primarily focused on cancer cell metabolism. Prior to teaming up with Dr. Sharma, he worked at NSP as a principal scientist where he was involved in pre-clinical discovery and clinical testing of novel formulations.


SELECTED PUBLICATIONS

Glutamine-dependent anapleurosis dictates glucose uptake and cell growth by regulating MondoA transcriptional activity. Kaadige MR, Looper RE, Kamalanaadhan S, and Ayer DE. (2009) Proc Natl Acad Sci USA 106(35): 14878-14883.

MondoA senses non-glucose sugars: regulation of thioredoxin-interacting protein (TXNIP) and the hexose transport curb. Stoltzman CA*, Kaadige MR*, Peterson CW, and Ayer DE. (2011) J Biol Chem 286(44): 38027-38034.

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, Scolyer RA, Rizos H, Lo RS, Cullinane C, Ayer DE, Ribas A, Johnstone RW, Hicks R, and McArthur GA.  (2014) Cancer Discov 4(4): 423-33.

MondoA:Mlx transcriptional activity is limited by mTOR-MondoA interactionKaadige MR, Yang J, Wilde BR, and Ayer DE. (2015) Mol Cell Biol 35(1):101-10.

Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Shen L, O’Shea JM, Kaadige MR, Cunha S, Wilde BR, Cohen AL, Welm AL, and Ayer DE. (2015) Proc Natl Acad Sci USA 112(17):5425-30.

Back To Top